Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/rarα

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Steinert, Gunnar ^a,b   Oancea, Claudia ^a   Roos, Jessica ^a   Hagemeyer, Heike ^b   Maier, Thorsten ^a   Ruthardt, Martin ^a   Puccetti, Elena ^b  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PLAKOGLOBIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; SULINDAC SULFIDE; WNT PROTEIN; DRUG DERIVATIVE; ONCOPROTEIN; PLZF RARALPHA FUSION PROTEIN, HUMAN; PLZF-RARALPHA FUSION PROTEIN, HUMAN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; SULINDAC; SULINDAC SULFONE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; APOPTOSIS; CYTOLOGY; DRUG EFFECT; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GAMMA CATENIN; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; PHENOTYPE; SIGNAL TRANSDUCTION; SULINDAC; TIME FACTORS; WNT PROTEINS;

EID: 79960447817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022540     Document Type: Article

References (53)

1. Puccetti E, Ruthardt M, (2004) Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. Leukemia 18: 1169-1175.
2. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, et al. (2009) Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457: 51-56.
3. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, et al. (2004) Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 103: 3535-3543.
4. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, et al. (2004) Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 24: 2890-2904.
5. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, et al. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423: 409-414.
6. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, et al. (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.
7. Chesire DR, Ewing CM, Gage WR, Isaacs WB, (2002) In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679-2694.
8. Chesire DR, Isaacs WB, (2003) Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 10: 537-560.
9. Giles RH, van Es JH, Clevers H, (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24.
10. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53-57.
11. Li H, Pamukcu R, Thompson WJ, (2002) beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 1: 621-625.
12. Li Y, Hively WP, Varmus HE, (2000) Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19: 1002-1009.
13. Tetsu O, McCormick F, (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
14. Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, et al. (1999) DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol 19: 4414-4422.
15. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, et al. (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 274: 10681-10684.
16. Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J, Nusse R, (1995) The dishevelled protein is modified by wingless signaling in Drosophila. Genes Dev 9: 1087-1097.
17. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793-803.
18. Fagotto F, Gluck U, Gumbiner BM, (1998) Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 8: 181-190.
19. Yost C, Torres M, Miller JR, Huang E, Kimelman D, et al. (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10: 1443-1454.
20. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
21. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, et al. (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90: 224-229.
22. Brown WA, Skinner SA, Vogiagis D, O'Brien PE, (2001) Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer. Dig Dis Sci 46: 2314-2321.
23. Dihlmann S, Klein S, Doeberitz Mv MK, (2003) Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2: 509-516.
24. Gardner SH, Hawcroft G, Hull MA, (2004) Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 91: 153-163.
25. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, et al. (2002) Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23: 107-114.
26. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101: 3118-3123.
27. Tegeder I, Pfeilschifter J, Geisslinger G, (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 15: 2057-2072.
28. Giardiello FM, Offerhaus JA, Tersmette AC, Hylind LM, Krush AJ, et al. (1996) Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 38: 578-581.
29. Chang WC, Everley LC, Pfeiffer GR, 2nd, Cooper HS, Barusevicius A, et al. (2005) Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC. Ann N Y Acad Sci 1059: 41-55.
30. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, et al. (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 59: 3387-3391.
31. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
32. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, et al. (2007) Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92: 323-331.
33. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, et al. (2003) Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892.
34. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, et al. (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6: 78-89.
35. Ray GF, Lanman RC, Fu CJ, Paranka NS, Pamukcu R, et al. (1995) Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. J Pharm Biomed Anal 14: 213-220.
36. Lavau C, Szilvassy SJ, Slany R, Cleary ML, (1997) Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. Embo J 16: 4226-4237.
37. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452.
38. Coulombel L, (2004) Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 23: 7210-7222.
39. Dihlmann S, von Knebel Doeberitz M, (2005) Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 113: 515-524.
40. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
41. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, et al. (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650-1653.
42. Kasum CM, Blair CK, Folsom AR, Ross JA, (2003) Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomarkers Prev 12: 534-537.
43. Pogoda JM, Katz J, McKean-Cowdin R, Nichols PW, Ross RK, et al. (2005) Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Cancer 114: 634-638.
44. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, et al. (2000) Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60: 3338-3342.
45. Herrmann C, Block C, Geisen C, Haas K, Weber C, et al. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene 17: 1769-1776.
46. Huang Y, He Q, Hillman MJ, Rong R, Sheikh MS, (2001) Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61: 6918-6924.
47. Lee HK, Jeong S, (2006) Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3′-UTR. Nucleic Acids Res 34: 5705-5714.
48. Steinbrink SD, Pergola C, Buhring U, George S, Metzner J, et al. (2010) Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 67: 797-806.
49. Matsuzawa SI, Reed JC, (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7: 915-926.
50. Fanelli M, Fantozzi A, De Luca P, Caprodossi S, Matsuzawa S, et al. (2004) The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J Biol Chem 279: 5374-5379.
51. Moon Y, Kim JI, Yang H, Eling TE, (2008) Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways. Life Sci 82: 591-599.
52. Cobas M, Wilson A, Ernst B, Mancini SJ, MacDonald HR, et al. (2004) Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 199: 221-229.
53. Jeannet G, Scheller M, Scarpellino L, Duboux S, Gardiol N, et al. (2008) Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 111: 142-149.